Novartis Wins US Court Appeal After Challenge to Gilenya Patent
January 04 2022 - 2:22AM
Dow Jones News
By Ed Frankl
Novartis AG said Tuesday that a U.S. appeals court has upheld
the exclusivity of its multiple-sclerosis blockbuster drug
Gilenya.
In August 2020, a U.S. federal court in Delaware blocked Chinese
drugmaker HEC Pharma Co. from selling a generic version of the drug
until the expiration of the Gilenya patent in December 2027, the
Swiss company said.
"This decision confirms the validity of the patent and allows
that injunction to remain in place," Novartis said.
"With this decision, Novartis confirms that it expects no
generic versions of Gilenya in the U.S. market for at least the
next two years," it said.
Novartis has already entered into settlement agreements with
filers for a generic version of Gilenya, though they will not be
able to launch a version before an agreed-upon date prior to
December 2027.
The potential generic entry date is confidential, the
Basel-based company said.
Write to Ed Frankl at edward.frankl@dowjones.com
(END) Dow Jones Newswires
January 04, 2022 02:07 ET (07:07 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024